Novartis’ inhaler beats GSK’s Seretide on cutting COPD measure
The New England Journal of Medicine has published a clinical trial showing that Novartis’ Ultibro Breezhaler outshone GlaxoSmithKline’s Seretide on reducing COPD flare-ups, which could challenge the current reliance on inhaled corticosteroids.
Read More
